Shared Decision-Making for Advanced Renal Cell Carcinoma: Focus on Adverse Event Management of Axitinib Plus IO: A Vodcast

Abstract Shared decision-making is essential to the care of patients with advanced renal carcinoma which can empower patients and help the healthcare team understand the patient’s goals of care. An important topic during the shared-decision making process is identification and management of treatmen...

Full description

Saved in:
Bibliographic Details
Main Authors: Edwin M. Posadas, Nancy Moldawer, Greg Biddulph, Dharanija Rao
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-04-01
Series:Oncology and Therapy
Subjects:
Online Access:https://doi.org/10.1007/s40487-025-00330-w
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850224021061238784
author Edwin M. Posadas
Nancy Moldawer
Greg Biddulph
Dharanija Rao
author_facet Edwin M. Posadas
Nancy Moldawer
Greg Biddulph
Dharanija Rao
author_sort Edwin M. Posadas
collection DOAJ
description Abstract Shared decision-making is essential to the care of patients with advanced renal carcinoma which can empower patients and help the healthcare team understand the patient’s goals of care. An important topic during the shared-decision making process is identification and management of treatment-related adverse events. A patient author and two healthcare professionals with real-world experience provide insight into the importance of shared decision-making and its utility in the management of treatment-related adverse events in patients with renal cell carcinoma who are receiving axitinib in combination with an immunotherapy agent.
format Article
id doaj-art-37b7ec01af334ffb904de67158f332c8
institution OA Journals
issn 2366-1070
2366-1089
language English
publishDate 2025-04-01
publisher Adis, Springer Healthcare
record_format Article
series Oncology and Therapy
spelling doaj-art-37b7ec01af334ffb904de67158f332c82025-08-20T02:05:45ZengAdis, Springer HealthcareOncology and Therapy2366-10702366-10892025-04-0113226327410.1007/s40487-025-00330-wShared Decision-Making for Advanced Renal Cell Carcinoma: Focus on Adverse Event Management of Axitinib Plus IO: A VodcastEdwin M. Posadas0Nancy Moldawer1Greg Biddulph2Dharanija Rao3Division of Medical Oncology, Department of Medicine, Cedars Sinai Medical Center and Center for Uro-Oncology Research Excellence (CURE)Division of Medical Oncology, Department of Medicine, Cedars Sinai Medical Center and Center for Uro-Oncology Research Excellence (CURE)Patient AuthorPfizer Inc.Abstract Shared decision-making is essential to the care of patients with advanced renal carcinoma which can empower patients and help the healthcare team understand the patient’s goals of care. An important topic during the shared-decision making process is identification and management of treatment-related adverse events. A patient author and two healthcare professionals with real-world experience provide insight into the importance of shared decision-making and its utility in the management of treatment-related adverse events in patients with renal cell carcinoma who are receiving axitinib in combination with an immunotherapy agent.https://doi.org/10.1007/s40487-025-00330-wShared decision-makingAdvanced renal cell carcinomaAdverse event managementAxitinibImmunotherapy
spellingShingle Edwin M. Posadas
Nancy Moldawer
Greg Biddulph
Dharanija Rao
Shared Decision-Making for Advanced Renal Cell Carcinoma: Focus on Adverse Event Management of Axitinib Plus IO: A Vodcast
Oncology and Therapy
Shared decision-making
Advanced renal cell carcinoma
Adverse event management
Axitinib
Immunotherapy
title Shared Decision-Making for Advanced Renal Cell Carcinoma: Focus on Adverse Event Management of Axitinib Plus IO: A Vodcast
title_full Shared Decision-Making for Advanced Renal Cell Carcinoma: Focus on Adverse Event Management of Axitinib Plus IO: A Vodcast
title_fullStr Shared Decision-Making for Advanced Renal Cell Carcinoma: Focus on Adverse Event Management of Axitinib Plus IO: A Vodcast
title_full_unstemmed Shared Decision-Making for Advanced Renal Cell Carcinoma: Focus on Adverse Event Management of Axitinib Plus IO: A Vodcast
title_short Shared Decision-Making for Advanced Renal Cell Carcinoma: Focus on Adverse Event Management of Axitinib Plus IO: A Vodcast
title_sort shared decision making for advanced renal cell carcinoma focus on adverse event management of axitinib plus io a vodcast
topic Shared decision-making
Advanced renal cell carcinoma
Adverse event management
Axitinib
Immunotherapy
url https://doi.org/10.1007/s40487-025-00330-w
work_keys_str_mv AT edwinmposadas shareddecisionmakingforadvancedrenalcellcarcinomafocusonadverseeventmanagementofaxitinibplusioavodcast
AT nancymoldawer shareddecisionmakingforadvancedrenalcellcarcinomafocusonadverseeventmanagementofaxitinibplusioavodcast
AT gregbiddulph shareddecisionmakingforadvancedrenalcellcarcinomafocusonadverseeventmanagementofaxitinibplusioavodcast
AT dharanijarao shareddecisionmakingforadvancedrenalcellcarcinomafocusonadverseeventmanagementofaxitinibplusioavodcast